SS Innovations Advances Telerobotic Surgery with 195 Remote Procedures, 244 Systems Installed

SS Innovations International Inc. (NASDAQ: SSII) is demonstrating that telerobotic surgery is no longer a distant concept but a rapidly advancing reality, according to a recent MedTech Dive report. The company's SSi Mantra system has been used in 195 robotic telesurgeries as of September 28, 2026, including cardiac procedures and long-distance operations. This progress places SS Innovations at the center of a growing market for remote surgical technology.

The company's installed base reached 244 SSi Mantra systems as of September 28, up 45% from the end of 2025. Cumulative procedures across all systems totaled 14,503, reflecting both growing adoption and clinical experience. These figures underscore the scale of SS Innovations' expansion as it seeks to make telerobotic surgery a standard option for patients and providers.

CEO Dr. Sudhir Srivastava, a cardiac surgeon and founder of SS Innovations, told MedTech Dive that robotic surgery is inherently a form of teleoperation. The central technical question, he said, is how much distance can be introduced without compromising responsiveness. The company's experience with long-distance operations is helping to answer that question, with cardiac-surgery programs recently launched in Colombia and Sri Lanka, and a new program established at HCG Hospital in Ahmedabad. The SSi Mantra system has now expanded into 12 countries.

For Texas, this news matters because the state is a hub for medical innovation and advanced manufacturing. As SS Innovations pursues U.S. FDA clearance and European Union CE marking, the company's growth could spur demand for specialized components, engineering talent, and clinical partnerships. Texas businesses in the medical device supply chain, as well as hospitals exploring telerobotic surgery, may find new opportunities as remote procedures gain ground.

The MedTech Dive article, titled “Telerobotic surgery is advancing around the world. Will the US embrace it?,” examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery. It highlighted SS Innovations alongside larger medical-device companies and emerging robotics developers. For more details, see the full report at https://ibn.fm/4ZLvL.

Investors and industry observers can follow SS Innovations' progress through the company's newsroom at https://ibn.fm/SSII. The latest updates relating to SSII are available there, providing insight into regulatory milestones and clinical adoption. For a broader view of the company's positioning, a detailed article is available at Read More>>.

The implications extend beyond SS Innovations. Telerobotic surgery could improve access to specialized care in underserved regions, reduce travel burdens for patients, and enable expert surgeons to operate remotely. As regulatory bodies in the U.S. and Europe evaluate these technologies, companies like SS Innovations are building the clinical evidence and infrastructure needed for broader acceptance. Texas, with its strong medical and technology sectors, is well positioned to benefit from these developments.

MissionIR, a specialized communications platform, supports companies like SS Innovations in enhancing visibility within the investment community. It is part of the Dynamic Brand Portfolio at IBN, which offers services including wire distribution through InvestorWire and editorial syndication to 5,000+ outlets. These resources help emerging companies reach investors and stakeholders as they scale.

As telerobotic surgery gains traction, SS Innovations' growing procedure volume and international footprint signal that remote operations are moving from demonstration to routine practice. The company's pursuit of FDA clearance and CE marking will be key milestones to watch, with potential ripple effects across the medical technology landscape and in states like Texas that are invested in healthcare innovation.